Celiac Disease Market Size to Reach USD 1,434.2 Million by 2032 growing at 10.2% CAGR - Exclusive Report by Acumen Research and Consulting

Author: Acumen Research and Consulting

According to Acumen Research & Consulting, the global Celiac Disease Market was valued USD 551.3 Million in 2022 and is estimated to be worth USD 1,434.2 Million by 2032, rising at a CAGR of 10.2% over the forecast period

The celiac disease market is constantly expanding, owing to increased awareness, improving diagnostic rates, and the illness's rising prevalence. The number of identified cases, demand for gluten-free products, advances in diagnostic procedures, and research and development activities for novel treatment options all has an impact on market size. Global pharmaceutical businesses such as Amgen, F. Hoffmann-La Roche Ltd, and Takeda Pharmaceutical Company Limited, as well as smaller biotech firms such as Innovate Biopharmaceuticals and ImmunogenX, LLC, are key competitors in the industry. These firms are actively involved in the development of celiac disease diagnostic tests, therapeutic drugs, and other treatment alternatives.

With continued research and development, the competitive landscape of the celiac disease industry is changing. Companies are concentrating their efforts on creating new medicines, enhancing diagnostic procedures, and broadening the range of gluten-free products. Product innovation, pricing tactics, partnerships, and collaborations fuel market rivalry. Companies are attempting to accommodate the increased demand for gluten-free products by offering a wide range of gluten-free alternatives.

The celiac disease market is being shaped by several developments. These include rising demand for gluten-free products, more investment in R&D, breakthroughs in diagnostic tools, and the rise of personalized medicine approaches to celiac disease therapy. Patient education and support programmes are also becoming more important, as they play an important role in illness management and patient outcomes.

Celiac Disease Market Statistics

Celiac Disease Market Statistics

  • With a 10.2% CAGR (2023-2032), the worldwide celiac disease market revenue is estimated to reach USD 551.3 Million in 2022
  • North America represented over 37% of the celiac disease market share in 2022
  • The Asia-Pacific celiac disease market growth is expected to rise at a CAGR of more than 11% between 2023 and 2032
  • The gluten free diet treatments covered over 41% share of treatments in 2022
  • Based on route of administrations, the oral occupied US$ 336.3 billion in 2022
  • Expansion of gluten-free food and beverage industry is the new celiac disease market trend

Request for a sample of this premium research report@ https://www.acumenresearchandconsulting.com/request-sample/3249

Celiac Disease Market Dynamics

Increasing Awareness and Diagnosis of Celiac Disease Fuels the Celiac Disease Market Value

Increased celiac disease knowledge and diagnosis have had a substantial influence on the celiac disease industry. As the general public becomes more aware of celiac disease, more people seek medical assistance for their symptoms, leading to an increase in diagnostic rates. This trend has been fueled by a variety of causes, including educational campaigns, advocacy activities, and increased illness understanding among healthcare providers.

The increase in knowledge has been crucial in finding undiagnosed celiac disease cases. Many celiac disease patients may have symptoms for years before getting a thorough diagnosis. Increased knowledge has aided healthcare workers in recognizing celiac disease's signs and symptoms, resulting in more accurate and prompt diagnosis.

Increased knowledge of celiac disease has resulted in an increase in demand for diagnostic testing. To confirm a diagnosis, healthcare practitioners are increasingly likely to undertake serological tests, genetic testing, and endoscopic biopsies. As a result, diagnostic accuracy has increased and we have a better grasp of the frequency of celiac disease in the public.

The market is being impacted by increased knowledge and diagnosis of celiac disease in two ways. For starters, it has resulted in a bigger patient pool seeking treatment choices, resulting in a rising market for pharmaceutical businesses, biotech corporations, and gluten-free goods makers. As more people are diagnosed with celiac disease, there is a greater need for gluten-free alternatives, therapeutic drugs, and diagnostic instruments.

Second, increased awareness has fueled field research and development activities. Pharmaceutical and biotech businesses are investing in the development of novel treatments and treatment options for celiac disease. This involves looking at novel pharmacological candidates, immunotherapies, and therapeutic interventions to combat the autoimmune response caused by gluten consumption.

Increased Research and Development for Celiac Disease Management Will Generate Surplus Celiac Disease Market Opportunities

Increased research and development (R&D) for celiac disease management has been critical in developing disease knowledge and therapy. The increasing incidence of celiac disease, the need for more effective therapeutic alternatives, and the desire to enhance the quality of life for those suffering from the condition have all fueled the focus on R&D. The creation of diagnostic tools is one area of research and development in celiac disease management. Researchers are attempting to improve diagnostic accuracy and efficiency in order to detect celiac disease earlier. This involves the development of novel serological tests, genetic testing procedures, and non-invasive diagnostic methods. The objective is to improve diagnostic speed and accuracy, allowing for timely intervention and treatment commencement.

The discovery of therapeutic strategies for celiac disease is another important field of study. While a gluten-free diet is the primary treatment method, researchers are looking at new drugs and therapies to ease symptoms, improve gut repair, and control the immunological response caused by gluten. This involves looking into new medication candidates, immunomodulators, and immunotherapies that particularly target celiac disease's autoimmune component. Furthermore, studies are being conducted to better understand the underlying causes and pathophysiology of celiac disease. This study contributes to the understanding of the intricate connections between genetic, environmental, and immunological elements involved in the disease's genesis and progression. It also sheds light on prospective biomarkers for illness diagnosis, disease monitoring, and therapy response evaluation.

Collaborations between pharmaceutical corporations, academic institutions, and research organizations have resulted from expanded R&D initiatives. These collaborations seek to speed the discovery of novel medicines, promote information sharing, and facilitate clinical studies to assess the safety and efficacy of new interventions.

Overall, growing research and development for celiac disease management demonstrates a dedication to improve the lives of those affected by the illness. These initiatives have the potential to result in innovative diagnostic tools, more effective medicines, and a better knowledge of the illness, ultimately leading to better management techniques and improved results for celiac disease patients.

Celiac Disease Market Segmentation

The global market has been categorized into treatment, route of administration, end-user, distribution channel, and regions

  • The treatment segment is split into infliximab, larazotide acetate, gluten free diet, and others
  • Route of administration segment includes oral and parenteral
  • End-user segment is split into hospitals, homecare, and others
  • Hospital Pharmacy, online pharmacy, and retail pharmacy are covered under the distribution channel segment
  • The market is divided into five regions that are North America, Europe, Latin America, Asia-Pacific, and The Middle East and Africa (MEA)

Celiac Disease Market Share

According to the celiac disease market forecast, the gluten free diet sub-segment will have the largest market share between 2023 and 2032.

According to the celiac disease industry analysis, the parenteral mode of administration application sub-segment accounted for a substantial market share in 2022 and is likely to do so in the years ahead.

Hospitals are one of the top end-users and will continue to be so in the future years, while the homecare sub-segment is predicted to develop at the quickest pace between 2023 and 2032.

Retail pharmacy has the highest market share in the distribution channel group; however internet pharmacy will acquire substantial traction throughout the anticipated timeframe.

Celiac Disease Market Regional Outlook

Celiac disease is reasonably well-known and diagnosed in North America, notably in the United States. The region boasts a well-developed healthcare infrastructure, innovative diagnostic procedures, and a sizable gluten-free market. The existence of significant market players, research activities, and supporting government regulations all contribute to the growth of the North American celiac disease market.

The prevalence of celiac disease varies by country in Asia-Pacific. Some countries, like as India, have lower rates of diagnosis and awareness. However, in nations such as China, Japan, and Australia, there is a growing trend of urbanization, changing dietary patterns, and more knowledge of celiac disease. This region's market is predicted to rise as a result of growing diagnosis rates, improved healthcare infrastructure, and more gluten-free product offers.

Celiac Disease Market Players

Some prominent celiac disease companies covered in the industry include Amgen, Anokion SA, BioLineRx Ltd, ChemoCentryx, Inc, COUR Pharmaceutical, F. Hoffmann-La Roche Ltd, ImmunogenX, LLC, Innovate Biopharmaceuticals, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.

Celiac Disease Business Strategies

  • In May 2023, Amgen disclosed favorable Phase 2 clinical trial findings for an experimental celiac disease therapy. In individuals with refractory celiac disease, the study found a substantial reduction in symptoms and an improvement in quality of life.
  • Anokion SA has concluded a successful Series B fundraising transaction, obtaining $100 million in March 2023. The money will help the business improve its antigen-specific immunological tolerance platform for the treatment of autoimmune illnesses including celiac disease.

Click here to buy the Premium Market Research report https://www.acumenresearchandconsulting.com/buy-now/0/3249

Receive our personalized services and customization by clicking here https://www.acumenresearchandconsulting.com/request-customization/3249

Mr. Frank Wilson

Acumen Research and Consulting

USA: +13474743864

India: +918983225533

E-mail: sales@acumenresearchandconsulting.com